New Alzheimer's drug enters first human safety trials
NCT ID NCT06657768
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 34 times
Summary
This early-stage trial tests an experimental drug called LY4006895 in healthy volunteers and people with early symptomatic Alzheimer's disease. The main goal is to check if the drug is safe and how the body processes it. The study has two parts: a single dose in healthy people and multiple doses in Alzheimer's patients, lasting up to 61 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aqualane Clinical Research
NOT_YET_RECRUITINGNaples, Florida, 34105, United States
Contact Phone: •••-•••-••••
Contact
-
Atlanta Center of Medical Research
RECRUITINGAtlanta, Georgia, 30331, United States
Contact Phone: •••-•••-••••
Contact
-
CenExel iResearch, LLC (CenExel iRA)
RECRUITINGDecatur, Georgia, 30030, United States
Contact Phone: •••-•••-••••
Contact
-
CenExel-HRI
RECRUITINGMarlton, New Jersey, 08053, United States
Contact Phone: •••-•••-••••
Contact
-
Collaborative Neuroscience Network - CNS
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-••••
Contact
-
Duke Early Phase Research Unit
NOT_YET_RECRUITINGDurham, North Carolina, 27710, United States
Contact Phone: •••-•••-••••
Contact
-
K2 Medical Research
RECRUITINGMaitland, Florida, 32751, United States
Contact Phone: •••-•••-••••
Contact
-
K2 Medical Research - Tampa
NOT_YET_RECRUITINGTampa, Florida, 33634, United States
Contact Phone: •••-•••-••••
Contact
-
K2 Medical Research - The Villages
RECRUITINGLady Lake, Florida, 32159, United States
Contact Phone: •••-•••-••••
Contact
-
National Center for Geriatrics and Gerontology
NOT_YET_RECRUITINGŌbu, 4748511, Japan
Contact Phone: •••-•••-••••
Contact
-
Progressive Medical Research
NOT_YET_RECRUITINGPort Orange, Florida, 32127, United States
Contact Phone: •••-•••-••••
Contact
-
QUEST Research Institute
NOT_YET_RECRUITINGFarmington Hills, Michigan, 48334, United States
Contact Phone: •••-•••-••••
Contact
-
The University of Tokyo Hospital
NOT_YET_RECRUITINGBunkyō City, 113-8654, Japan
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4006895 (an experimental drug given intravenously)
What this could lead to
If successful, this could pave the way for a new treatment option for early Alzheimer's disease.
What could go wrong
This is a very early Phase 1 trial focused only on safety and dosing. It is too small and early to know if the drug works, and many drugs fail at this stage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.